Stock Scorecard
Stock Summary for Cabaletta Bio Inc (CABA) - $2.50 as of 12/9/2025 8:22:07 PM EST
Total Score
10 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CABA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CABA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CABA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CABA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CABA (28 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for CABA
Company Overview |
|
|---|---|
| Ticker | CABA |
| Company Name | Cabaletta Bio Inc |
| Country | USA |
| Description | Cabaletta Bio, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of advanced T-cell therapies aimed at targeting B-cell-mediated autoimmune diseases. With a robust pipeline driven by proprietary research and a commitment to improving patient outcomes, the company is positioned to transform treatment paradigms in this sector. Leveraging its expertise in immunotherapy and focusing on patient-centric initiatives, Cabaletta Bio presents an attractive investment opportunity for institutional investors looking to capitalize on innovative solutions in the biopharmaceutical industry. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.50 |
| Price 4 Years Ago | 3.79 |
| Last Day Price Updated | 12/9/2025 8:22:07 PM EST |
| Last Day Volume | 1,760,944 |
| Average Daily Volume | 4,343,562 |
| 52-Week High | 3.67 |
| 52-Week Low | 0.99 |
| Last Price to 52 Week Low | 152.53% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 44.34 |
| Sector PE | 52.63 |
| 5-Year Average PE | -4.65 |
| Free Cash Flow Ratio | 3.97 |
| Industry Free Cash Flow Ratio | 14.50 |
| Sector Free Cash Flow Ratio | 28.62 |
| Current Ratio Most Recent Quarter | 3.60 |
| Total Cash Per Share | 0.63 |
| Book Value Per Share Most Recent Quarter | 1.45 |
| Price to Book Ratio | 1.76 |
| Industry Price to Book Ratio | 34.36 |
| Sector Price to Book Ratio | 33.49 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.13 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 96,265,000 |
| Market Capitalization | 240,662,500 |
| Institutional Ownership | 74.15% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -71.21% |
| Reported EPS 12 Trailing Months | -2.40 |
| Reported EPS Past Year | -1.82 |
| Reported EPS Prior Year | -2.34 |
| Net Income Twelve Trailing Months | -158,523,000 |
| Net Income Past Year | -115,864,000 |
| Net Income Prior Year | -67,675,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 60,206,000 |
| Total Cash Past Year | 163,962,000 |
| Total Cash Prior Year | 193,238,000 |
| Net Cash Position Most Recent Quarter | 60,206,000 |
| Net Cash Position Past Year | 163,962,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 152,335,000 |
| Total Stockholder Equity Prior Year | 236,198,000 |
| Total Stockholder Equity Most Recent Quarter | 139,466,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -120,259,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.25 |
| Free Cash Flow Past Year | -90,433,000 |
| Free Cash Flow Prior Year | -54,236,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | -0.04 |
| 20-Day Bollinger Lower Band | 1.11 |
| 20-Day Bollinger Middle Band | 2.20 |
| 20-Day Bollinger Upper Band | 3.28 |
| Beta | 3.17 |
| RSI | 54.79 |
| 50-Day SMA | 1.99 |
| 150-Day SMA | 8.56 |
| 200-Day SMA | 7.08 |
System |
|
| Modified | 12/8/2025 7:49:06 PM EST |